AR059095A1 - Formas solidas de acido (4r) -1-(4-(2- cloro-5- fluorobenzoil) - amino-3- metoxibenzoil )-1,2,3,5- tetrahidro- espiro - (4h-1- benzacepin -4,1' -(2) ciclopenten) -3'- carboxilico - Google Patents

Formas solidas de acido (4r) -1-(4-(2- cloro-5- fluorobenzoil) - amino-3- metoxibenzoil )-1,2,3,5- tetrahidro- espiro - (4h-1- benzacepin -4,1' -(2) ciclopenten) -3'- carboxilico

Info

Publication number
AR059095A1
AR059095A1 ARP070100245A ARP070100245A AR059095A1 AR 059095 A1 AR059095 A1 AR 059095A1 AR P070100245 A ARP070100245 A AR P070100245A AR P070100245 A ARP070100245 A AR P070100245A AR 059095 A1 AR059095 A1 AR 059095A1
Authority
AR
Argentina
Prior art keywords
benzacepin
tetrahydro
amino
solid forms
metoxibenzoil
Prior art date
Application number
ARP070100245A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR059095A1 publication Critical patent/AR059095A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP070100245A 2006-01-20 2007-01-19 Formas solidas de acido (4r) -1-(4-(2- cloro-5- fluorobenzoil) - amino-3- metoxibenzoil )-1,2,3,5- tetrahidro- espiro - (4h-1- benzacepin -4,1' -(2) ciclopenten) -3'- carboxilico AR059095A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76042706P 2006-01-20 2006-01-20
US82378406P 2006-08-29 2006-08-29

Publications (1)

Publication Number Publication Date
AR059095A1 true AR059095A1 (es) 2008-03-12

Family

ID=38169264

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100245A AR059095A1 (es) 2006-01-20 2007-01-19 Formas solidas de acido (4r) -1-(4-(2- cloro-5- fluorobenzoil) - amino-3- metoxibenzoil )-1,2,3,5- tetrahidro- espiro - (4h-1- benzacepin -4,1' -(2) ciclopenten) -3'- carboxilico

Country Status (7)

Country Link
US (1) US20070173490A1 (enExample)
EP (1) EP1984342A2 (enExample)
JP (1) JP2009523806A (enExample)
AR (1) AR059095A1 (enExample)
CA (1) CA2637838A1 (enExample)
TW (1) TW200806631A (enExample)
WO (1) WO2007084591A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541807A (zh) 2006-09-22 2009-09-23 詹森药业有限公司 用作血管升压素拮抗剂的螺环苯并氮杂
WO2008036755A1 (en) 2006-09-22 2008-03-27 Janssen Pharmaceutica N.V. Spiro benzazepines used as vasopressin antagonists
US7943782B2 (en) * 2007-10-19 2011-05-17 Abbott Laboratories Crystalline chemotherapeutic

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
ATE189121T1 (de) * 1994-04-22 2000-02-15 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
ATE305454T1 (de) * 2000-07-05 2005-10-15 Ortho Mcneil Pharm Inc Nichtpeptidische substituierte spirobenzoazepine als vasopressin antagonisten
AU2001296950A1 (en) * 2000-10-05 2002-04-15 Merck & Co., Inc. Process for preparation of integrin receptor antagonist intermediates
AR044782A1 (es) * 2003-06-17 2005-10-05 Ortho Pharma Corp Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina
HRP20051005A2 (en) * 2003-06-17 2006-09-30 Janssen Pharmaceutica N.V. Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
JP3972103B2 (ja) * 2003-09-29 2007-09-05 国立大学法人 岡山大学 ピリドピリミジン骨格とステロイド骨格を内蔵する融合化合物及びその製造方法

Also Published As

Publication number Publication date
US20070173490A1 (en) 2007-07-26
TW200806631A (en) 2008-02-01
WO2007084591A2 (en) 2007-07-26
EP1984342A2 (en) 2008-10-29
JP2009523806A (ja) 2009-06-25
WO2007084591A3 (en) 2007-11-15
CA2637838A1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
TN2010000292A1 (en) 6h-dibenzo[b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
MX2010005070A (es) Derivados de piridazinona como inhibidores de parp.
MX2009007200A (es) Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
CY2020030I1 (el) Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλο)-κυκλοπροπανοκαρβοξαμιλο)-3-μεθυλοπυριδιν-3-υλο)-βενζοϊκου οξεος
WO2007138351A3 (en) Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
WO2008108958A8 (en) Benzimidazole derivatives and methods of use thereof
NZ595073A (en) Proline derivatives as cathepsin inhibitors
DK2336120T3 (da) Kombinationer, der indeholder amid-substituerede indazoler som poly(adp-ribose)polymerase (parp)-hæmmere
EA201070164A1 (ru) Твердый препарат, включающий алоглиптин и гидрохлорид метформина
HRP20141248T1 (en) 4-(indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as ep4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
CL2014000202A1 (es) Compuestos fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-alcoxi-3-metil-butil)-1h(1,2,4)triazol sustituidos; proceso para preparar dicho compuesto; uso de dichos compuestos para combatir hongos fitopatogenos.
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
GEP20146072B (en) New compounds
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
AR059095A1 (es) Formas solidas de acido (4r) -1-(4-(2- cloro-5- fluorobenzoil) - amino-3- metoxibenzoil )-1,2,3,5- tetrahidro- espiro - (4h-1- benzacepin -4,1' -(2) ciclopenten) -3'- carboxilico
MX2010005650A (es) Derivados de diazabicicloalcano substituidos con biarilo.
WO2010116380A3 (en) A one pot process for preparing 2-butyl-3-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro [4, 4] non-1-en-4-one (irbesartan)
WO2007122508A3 (en) An improved process for the preparation of irbesartan
CL2009001437A1 (es) Metodo para la preparacion de (1r, 2s, 3r)-1-(2-(isoxazol-3-il)-1h-imidazol-5-il)butano-1,2,3,4-tetraol utilizando isoxazol-3-carbonitrilo; y uno de los compuestos intermediarios considerados en la preparacion del isoxazol-3-carbonitrilo.
WO2010077928A3 (en) Flavononol renin inhibitor compounds and methods of use thereof
PE20090428A1 (es) Un nuevo procedimiento para preparar acido 2-(3-{6-[2-(2,4-diclorofenil)-etilamino]-2-metoxipirimidin-4-il}-fenil)-2-metil-propionico
UA110512C2 (ru) Композиція вірусного інгібітора для терапевтичного застосування
CL2007002408A1 (es) Procedimiento para preparar compuestos derivados de benzodiazepin-2-ona sustituidos, antagonistas de cgrp; compuestos intermediarios; y procedimiento para preparar compuestos intermediarios.
南野佳代 Deborah L. Rhode, Access to Justice
HK1147446A1 (en) Tetrazole compounds for reducing uric acid

Legal Events

Date Code Title Description
FA Abandonment or withdrawal